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Summary.-The hypoxic cell radiosensitizer desmethylmisonidazole (1-(2-nitro-
imidazol-1-yl)-2,3-propandiol; Ro 05-9963; DEMIS) was administered to 4 dogs at
doses of50 and 200 mg/kg by both oral and i.v. routes. The resulting plasma, cerebro-
spinal fluid and urinary concentrations were measured by HPLC analysis; various
pharmacokinetic parameters were obtained and compared with similar data for the
parent compound, misonidazole (MISO), in the dog.
Because of its shorter half-life (2.1 h) the total tissue exposure for DEMIS was only
half that for a similar dose of MISO, whereas peak plasma concentrations were 60%
higher than those for MISO. Cerebrospinal fluid penetration by DEMIS was limited
because ofthe drug's reduced lipophilicity, and the total cerebrospinal-fluid exposure
to the drug during the first 5 h after drug administration was about half that pre-
viously recorded for MISO.
Urinary excretion accounted for75%o of the i.v. dose of unchanged DEMIS, whilst
less than 20% of MISO is excreted via this route.
DEMIS was also administered to 6 dogs bearing spontaneous tumours at a dose
of 150 mg/kg i.v., and the resulting concentrations were recorded in serial biopsies
over a 5h period.
Mean tumour/plasma ratios ranged between 56 and 90 O, and were very similar
to those previously observed for MISO in canine tumours. Peak DEMIS tumour
concentrations, however, occurred rapidly after dosage (15-20 min) and were as
much as twice those for MISO, although they declined rapidly from their initial
concentration.
We conclude in the light of the reduced tissue exposure, particularly of the nervous
tissue, and the improved tumour concentrations, that DEMIS may prove to be a
potentially less toxic alternative to MISO.
THE USE of hypoxic cell radiosensitizing
drugs, in particular the nitroimidazole
series, is currently attracting considerable
interest. Several clinical trials are in
progress to assess the 2-nitroimidazole,
misonidazole, (1-(2-nitroimidazol-1-yl)-3-
methoxypropan-2-ol; Ro 07-0582; MIS)
which appears to be the most effective
drug yet available (Dische et al., 1977;
Urtasun et al., 1977; Wiltshire et al., 1978).
However, the clinical use of MISO in man
is limited by its neurotoxicity, particularly
peripheral neuropathies, and a total dose
not exceeding 12 g/m2 is now recommen-
ded (Dische et al., 1977). This dose limita-
tion means that where the drug is given at
low doses (e.g. 0-6 g/m2) with each fraction
of a conventional multi-fraction radio-
therapy regime, the resulting enhancement
ratios are unlikely to exceed 1a2-1a3.
Alternatively the drug may be adminis-
tered at a high dose (e.g. 3 g/m2) with
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fewer fractions. Efforts have therefore
been made to develop less toxic alterna-
tives than MISO which possess similar or
greater electron affinities (Brown et al.,
1978; Wardman et al., 1978; Adams et at.,
1979a, b).
Desmethylmisonidazole (1-(2-nitroimi-
dazol-1-yl)-2,3-propandiol; Ro 05-9963;
DEMIS) is a major metabolite of MISO,
formed by its 0-demethylation and found
in the plasma of several species, including
man, after the administration of MISO
(Flockhart et al., 1978a; Workman et al.,
1978). Investigation of its radiosensitizing
properties suggest that it is as effective as
MISO, whilst its acute LD50isgreater than
that of MISO in mice (Adams et al., 1976;
Flockhart et al., 1978b; Brown et al., 1979).
Because ofthe disparities in the pharmaco-
kinetic behaviour of related nitroimida-
zoles in mice (Brown et al., 1979; Work-
man P., in preparation) there may be
considerable problems associated with the
use ofrodent species in new drug develop-
ment. However, our previous studies have
suggested that the dog may have advan-
tages over rodents in this respect (White
et al., 1979a, b). Therefore in the present
study we have investigated the pharmaco-
kinetics and tumour-penetrating proper-
ties of DEMIS in the dog.
MATERIAL AND METHODS
Experimental dogs
The 4 experimental dogs used in this study
were adult, male and crossbred, weighing 12
to 18 kg. All dogs were clinically normal, and
their routine haematological and biochemical
parameters were monitored before and during
the study.
DEMIS (Roche Products, Ltd) was pre-
pared for i.v. injection at a concentration of
5% in0.9% NaCl solution. It was packed into
N. 00 gelatin capsules for oral administration,
each capsule containing 0 4 g of the drug.
The details for administration of the drug,
and the subsequent sampling techniques, are
as described previously for MISO (White etal.,
1979a).
(a) Dogs 1 and 2 (16 and 12 kg respectively)
each received i.v. bolus injections of DEMIS
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at a dose of 50 mg/kg. Dogs 3 and 4 (both
18 kg) received 200 mg/kg by the same route.
The urine from Dogs 1 and 3 was collected
over the next 48 h. Seven days later each dog
received DEMIS again, atthe previous dosage
but orally.
(b) One month later Dogs 1 and 3 received
DEMIS i.v. injections at the previous dosage
(50 and 200 mg/kg respectively). Both dogs
were then immediately anaesthetized by the
i.v. injection of sodium pentobarbitone at a
dose of 30 mg/kg and blood and CSF samples
were then removed using the technique
described by White et al. (1979b).
All plasma, CSF, tissue and urine samples
were stored at-20°C before assayfor DEMIS
using high-performance liquid chromato-
graphy (HPLC) as described by Workman
et al. (1978). The pharmacokinetics ofDEMIS
could be described by a two-compartment
open model (see Results) and the various
pharmacokinetic parameters were estimated
from the resulting data in the following
manner.
The half-life of the elimination phase (t1/2)
was calculated from the equationtl,2=(ln2)/,B
where / is the terminal disposition phase rate
constant obtained from the slope of the log
plasma concentration x time plot by the
method ofleast-squares regression analysis.
Total tissue exposure or area under the
curve (AUC) of the plasma concentration x
time plot was calculated from the first sample
pointuntilno drugwasdetected intheplasma
(effectively zero to infinity) using Simpson's
Rule.
The plasma clearance (P,1) was derived
from the equation P,I=D/AUCO- ,. Vol-
umes of distribution (Vd) were calculated
for a two-compartment model using the
equation Vd=D/AUC.p where D is the dose.
Clinical material
Six dogs bearing spontaneous tumours
were presented at the Department ofClinical
Veterinary Medicine for radiation treatment.
Case 1.-A 6-year-old Hunt Terrier bitch
weighing 7 kg with a highly destructive lesion
of the ischium.
Case 2.-A 7-year-old German Shepherd
bitch weighing 31 kg with a tonsillar tumour.
Case 3.-A 10-year-old Labrador bitch,
weighing 30 kg, with a tumour involving the
frenulum and ventral aspect ofthe tongue.
Case 4.-A 7-year-old Bull Terrier dog,R. A. S. WHITE AND P. WORKMAN
weighing 24 kg, with a destructive tumour
of the distal radius. This case was judged by
the 2 clinicians as being incurable and
having reached a terminal stage.
Case 5.-A 6-year-old Labrador dog,
weighing 40 kg, with a tumour of the pre-
maxilla and anterior palate.
Case 6.-A 5-year-old Labrador dog,
weighing 35 kg, with metastasis of a sub-
mandibular lymph node following the suc-
cessful excision and irradiation of a fibro-
sarcoma of the skin in the cervical region.
DEMIS was administered to all dogs at a
dose of 150 mg/kg by i.v. injection. With the
exception of Case 4, all dogs wAere then
anaesthetized with sodium pentobarbitone
at a dose of 30 mg/kg. Small tumour biopsy
specimens (> 10 mg) and blood samples
were removed at various times.
A blood sample was removed from Case 4
15 min after drug administration, and euthan-
asia was then carried out with sodium pento-
barbitone 20% (Euthatal, May and Baker).
Postmortem examination was then carried
out and tumour samples mere removed from
necrotic, haemorrhagic, cystic and 2 appar-
ently healthy areas of tumour.
Tumour samples from all dogs were imme-
diately placed in liquid N2 before storage and
assay.
RESULTS
Experimental dogs
Fig. 1 shows typical semilog plots of
plasma DEMIS concentrations vs time
for i.v. bolus doses of 50 and 200 mg/kg.
In every case the elimination of DEMIS
was bi-exponential and consistent with
a 2-compartment open model. However,
the initial distribution (o) phase was very
short, and effectively complete by 30 min
in all cases.
Fig. 2 shows the plasma DEMIS con-
centrations for Dog 4 after oral and i.v.
doses of 200 mg/kg. The data are plotted
on linear axes to demonstrate the rather
slow oral absorption of DEMIS. After
completion of the absorption phase the
elimination kinetics were similar to those
of the terminal disposition (/) phase for
the i.v. route.
Various pharmacokinetic parameters
are summarized in Table I.
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FIG. 1. LPlasma D)ETIS (Ro 05-9963) coii-
centratioins for 2 dlogs after (loses of 50 (0)
and 200 mg/kg (O) i.v. respectively.
Peak plasma DEMIS concentrations.
After i.v. administration the apparent
peak plasma DEMIS concentrations were
always seen in the first sample (at 5 min)
whereas after oral dosage the peak times
were variable and ranged between 5 min
and 3 h (median 2 h). Peak concentrations
were generally proportional to dose for
both routes ofadministration, though they
were considerably lower for the oral route.
Area under the curve (AUC). In 3 of
the 4 dogs the AUC after oral dosage was
markedly lower than that for i.v. dosage
(Table I) and the overall mean for the oral
bioavailability was 56 + 24% (s.d.) (Table
II). After i.v. dosage the resulting AUC
was closely related to dose, whereas that
after oral dosage was more variable.
Half-life (t112). Values for t1/2 ranged
between I-I and 2-9 h (Table I). In 3 ofthe
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TABLE 1.-Pharmacokinetic datafor Dogs 1-4 after oral and i.v. dosage ofDEMIS
Peak
plasma
concen- Peak
Dose tration time t1/2*
Dog (mg/kg) Route (pg/mi) (min) (h)
1 50 I.v. 75 5 2*7
(2.5-2.9)
Oral 25 120 1*4
(1 0-2 1)
2 50 I.V. 136 5 2 1
(1.8-2.4)
Oral 31 120 1.1
(049-1t6)
3 200 I.V. 377 5 2 9
(2.8-3-1)
Oral 153 5 1 4
(1.1-1.8)
4 200 L.v. 466 5 2 0
(1.0-2.1)
Oral 140 180 3 1
(2.9-3.4)
* 95% confidence limits in parentheses.
p AUC (h-1) (pg.h/ml)
0 25 247
0-50
0-33
0.51
0 23
0-49
0-35
0 22
Pci
(1/kg/h)
0-20
Vd
(1/kg)
0-81
87 0-57 1.15
255 0*20 0*59
124 0-40 0*79
1160 0-17 0-75
586 0-34 0 70
1070 0*19 0'53
973 0'21 0-93
c
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FIG. 2.-Plasma DEMIS concentrations for
Dog 4 after oral (*) and i.v. (0) dosage at
200 mg/kg.
4 dogs t1/2 after oral dosage (mean 1-8 +
0-9 h) was shorter than that after i.v.
dosage (mean 2-4 + 0-5 h). However, this
difference was not significant (P> 0 1)
because ofthe small numbers in this study.
There was no indication that t1/2 was dose-
dependent.
Plasma clearance (Pci).-Mean values
TABLE II.-Oral bioavailability ofDEMIS
in Dogs 1-4
Oral AUC
Dose I.v. AUC
(mg/kg) (%)
50 35
50 49
200 57
200 91
Mean 57
s.d. + 24
for P,j were found to be lower for the i.v.
route (0-19 + 0 02 1/kg/h) than for the oral
route (0.38 +0.15 1/kg/h s.d.). This was due
to the shorter t1/2 values and poor bio-
availability for the oral route in 3 of the
4 dogs.
Volumes ofdistribution (VVd).-Values of
Vd for the i.v. route, ranged from 0-53 to
0*81 (mean 0-67 + 0-03 1/kg). However, the
apparent Vd values calculated for the
oral route were higher in all 4 dogs (mean
0-89 + 0-20 1/kg). The main reason for this
was the poor bioavailability, which pre-
vents accurate estimation of Vd after oral
administration.
Urinary exeretion.-The urinary excre-
tion of unchanged DEMIS was found to
account for 75.7% and 73.6% of the
original dose for Dogs 1 and 3 respectively.
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TABLE III.-P
concentrations
and 200 mg/l
Time
(h)
Dog 1 1
2
3
4
5
(/ug.h/ml)
AUC (0-5h)
Dog3 1
2
3
4
5
(pg.h/ml)
AUC (0-5h)
(ug.h/ml)
400 1
- 300 -
0
to ._
C.
@ 200 -
0
u
CO1
In o* 100 -
0
'lasma and CSF DEMIS No DEMIS was detected as the glucuro-
in Dogs 1 and 3 after 50 nide-conjugated form.
kg DEMIS i.v. respectively Cerebrospinal fluid concentrations.-
CSF/ After the administration of DEMIS at
Plasma CSF Plasma doses of50 and 200 mg/kg to Dogs 1 and 3
(pg/ml) (pg/ml) (%) respectively the drug was detected in the
56 8 14 CSF of both dogs in all samples up to 5 h.
33 217 42 The CSF and corresponding plasma con-
31 20 65 centrations for the 2 dogs are presented in
23 14 61 Table III, and the data for Dog 3 (200
mg/kg) are presented on a linear plot in
160 78 49 Fig. 3.
309 73 24 The CSF/plasma ratios continued to
288 91 32 rise from one to 5 h, reaching values up to
234 103 48 76%. The slow equilibration of the CSF
127 97 76 concentrations with those of the plasma
resulted in considerably lower AUC for
963 422 44 CSF than for plasma (49% and 44%,
respectively, for Dogs 1 and 3, see Table
III).
Clinical material
The histopathological identification of
the tumours in Cases 1-6 are presented in
Table IV.
The plasma and tumour DEMIS con-
centrations for the various tumours are
recorded in Table V.
For illustrative purposes the data for
Case 5 (fibrosarcoma ofpalate) are plotted
on linear axesin Fig. 4.
TABLE IV.-Histopathological identifica-
tion of tumours in Cases 1-6
Case Histological type
1 Fibrosarcoma
2 Squamous-cell
carcinoma
3 Squamous-cell
carcinoma
Comments
Invasive and well
differentiated
Well differentiated.
Some necrotic and
haemorrhagic areas.
Well differentiated.
-I
I I I I
1 2 3 4
Time (h)
5
FIG. 3.-Plasma (0) and CSF (0) DEMIS
concentrations after a dose of 200 mg/kg
i.v. and Na pentobarbitone anaesthesia.
4 Haemangiosarcoma Biopsy
1 Necrotic and
haemorrhagic.
2 Haemorrhagic.
3 Dermal invasion.
4 Bone invasion.
5 Cystic fluid.
5 Fibrosarcoma Well differentiated and
active
6 Fibrosarcoma Poorly differentiated
infiltrating normal lymph
nodes
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TABLE V.-Concentrations of DEMIS in
plasma and tumour biopsy specimens
after 150 mg/kg i.v.
Time Plasma Tumour
(h)(br grml) (ug/g)
Case 1: Fibrosarcoma (ischium)
1 157
2 144
3 144
4 131
5 142
Case 2: Tonsillar carcinoma
99
97
87
61
51
1 160 121
2 108 94
3 74 52
4 78 30
Case 3: Squamous-cell carcinoma
(min)
15 264 221
30 220 180
45 201 131
60 190 114
90 160 144
120 143 115
Samples
Concen-
tration
(pg/g)
Tumour/
Plasma
(%)
63
67
60
47
36
76
87
70
39
84
82
65
60
90
80
Tumour/
Plasma
(%)
Case 4: Haemangiosarcoma biopsy specimens
15 minafter injection
Plasma 311
Necrotic tumour 218 70
Haemorrhagic tumour 235 76
"Healthy" tumour 250 80
"Healthy" tumour 224 72
Cystic fluid 114 37
Overall mean + s.d. 208 + 54 67 + 17
Tumour/
Time Plasma Tumour Plasma
(min) (Kg/ml) (yg/g) (%)
Case 5: Fibrosarcoma (palate)
15 261 290 111
30 313 270 86
45 281 218 78
60 272 202 74
90 249 182 73
120 229 195 85
Case 6: Fibrosarcoma (lymph node)
20 393 404 103
40 360 329 91
80 335 226 68
120 198 195 98
Plasma DEMIS concentrations.-The
highest plasma concentrations of DEMIS
were recorded in all cases except Case 5
in the first sample. Peak concentrations
for those cases first sampled at 15 or 20
min (range 261-392 jug/ml) were con-
siderably greater than those first sampled
at 1 h (151 and 160 [g/ml). Plasma con-
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FIG. 4.-Plasma (0) and tumour (*) DEMIS
in a dog bearing a fibrosarcoma of the
palate after 150 mg/kg DEMIS i.v.
centrations fell rapidly from their petLk,
and plasma kinetics were generally similar
to those for theexperimental dogs (above).
Tumour DEMIS concentrations.-Tu-
mour/plasma concentration for DEMIS
ratios were generally similar for all the
tumours studied, and were independent
of time after injection, indicating rapid
equilibration with the plasma. Values
ranged between 36% and 111%, and mean
values varied from 56% to 90%. As with
plasma, the highest tumour concentra-
tions were obtained in the first sample,R. A. S. WHITE ANI) P. WORKMAN
and therefore those tumours biopsied at
the earliest times showed higher initial
concentrations.
Case 4 (Table V; haemangiosarcoma)
shows that the distribution ofDEMIS was
similar for necrotic, haemorrhagic and
apparently healthy tumour. The concen-
tration in the cystic fluid was, however,
rather lower.
DISCUSSION
We have investigated the pharmaco-
kinetic and tumour-penetrating properties
in the dog ofDEMIS, a hypoxic cell radio-
sensitizing drug as effective as MISO but
less toxic. The results are compared with
similar data for MISO in the dog (White
et al., 1979a, b).
The pharmacokinetic behaviour of
DEMIS administered i.v. in the dog can be
described by a 2-compartment open model,
involving an initial distribution (a) phase
lasting - 0 5 h and followed by a terminal
disposition (/) phase. A similar pharmaco-
kinetic pattern was obtained for MISO,
though the of phase was not so marked,
and often absent at low doses (50 and
100 mg/kg). Peak plasma concentrations
occurredimmediately afteri.v. administra-
tion of the drug, whereas those for MISO
overthe doserange 50-200 mg/kg occurred
rather later (mean range 0 3-0 8 h). Peak
DEMIS concentrations were found to be
more than 50% higher than those recorded
for a similar dose ofMISO.
Oral dosage produced variable and usu-
ally incomplete absorption ofDEMIS. The
oral bioavailability (57 + 24%) was con-
siderably less than that for MISO (92 +
100 %) which was completely absorbed.
The time ofthe peak plasma concentration
ofDEMIS after oral dosage (median 1-5 h)
was, however, similar to that for MISO
(median range 1-5-3 h).
Although tl/2 ofDEMIS was found to be
independent of dose, some variation was
noted between the 2 routes of administra-
tion in 3 ofthe 4 dogs (meant1/2 198 + 0 9 h
oral route; 2-4 + 0 5 h i.v.). Because of the
small numbers in this study the difference
was not significant (P > 0.1) and an overall
mean of 2-1 + 0-8 h was recorded. This
value is considerably shorter than that of
4.7 h (mean of oral and i.v. routes) for
MISO.
Because of the relatively short t1/2 of
DEMIS, and despite its higher initial peak
concentrations, the total tissue exposure
(plasma AUC) for the i.v. route was only
halfthat for a similar dose ofMISO.
The urinary excretion of unchanged
DEMIS accounted for three-quarters of
the original i.v. dose, whereas no drug was
recovered as the glucuronide-conjugated
form. In contrast, the urinary excretion of
unchanged MISO was only 4-7%, and the
total urinary recovery of MISO, the meta-
bolite DEMIS and the respective glucu-
ronides, was only 15-20% of the original
i.v. dose.
DEMIS penetrated the CSF much less
rapidly than MISO, and hence the total
CSF exposure to DEMIS, as estimated by
the AUCo_5h values, was only 44-490 of
the corresponding plasma value, compared
to 80-89% for MISO. In agreement with
these data, we have recently observed
relatively poor penetration of dog brain
by DEMIS, with concentrations ranging
between only 11 and 610% of the corre-
sponding plasma concentration compared
with 43-1170% for MISO (White et al., in
preparation).
Data for the tumour DEMIS concentra-
tions in Cases 1-6 indicated that the large
peak plasma concentrations recorded in
the pharmacokinetic study after i.v.
dosage were indeed reflected by high
initial tumour concentrations. The peak
tumour concentrations for DEMIS (range
218-404 jug/g) were considerably greater
than those previously recorded for MISO
(range 131-198 ,g/g). In all cases the peak
tumour DEMIS concentrations were re-
corded at the firstbiopsy. Tumour: plasma
ratios for DEMIS were, however, inde-
pendent oftime, andmaximumvalueswere
observed as early as 15-20 min, indicating
very rapid tumour penetration. Mean
values for the 6 tumours ranged from 56
to 90°/O (overall mean 74 + 13%) and were
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strikingly similar to the range of 47-9500
for MISO. As for MISO, the degree of
tumour penetration was generally similar
for a range of tumours of different histolo-
gical type, and the spatial distribution of
DEMIS in a haemangiosarcoma (Case 4)
indicated that the drug penetrated equally
well into necrotic, haemorrhagic and
"healthy" tumour tissue. The concentra-
tion in the cystic fluid of this tumour was
rather lower, but similar findings have
been madeforMISO in human tumour cyst
fluid (Flockhart et al., 1978a; Ash et al.,
1979; Workman et al., unpublished data).
It is pertinent to discuss the compara-
tive penetration properties of DEMIS and
MISO into both tumours and the central
nervous system. The values for the
volume ofdistribution for both drugs were
similar to that of total body water (0.6
1/kg) and indicate that both distribute
freely in the body compartments and
penetrate tissue well. However, it cannot
be inferred from these values that all
tissues would be equally well penetrated,
or that the 2 drugs would behave
similarlyinalltissues.MISOisconsiderably
more lipophilic than DEMIS (octanol/
water partition coefficients 0 43 and 0-11,
respectively); thus MISO will penetrate
lipoid membranes more rapidly than
DEMIS. This accounts for the poor ab-
sorption of DEMIS from the gastrointes-
tinal tract and its slower penetration
across the blood/CSF barrier. On the
other hand, this difference in lipophilicity
did not cause any disparity in gross
tumour penetration and indicates a less
severe lipoid barrier at the plasma/tumour
interface. A similar difference in penetra-
tion of DEMIS into brain and tumour has
also been found in the mouse (XVorkman,
1979; Brown & Workman, in preparation).
In view of the pharmacokinetic and
tumour penetration data described above,
it is worth while considering the possible
relative advantages and disadvantages
ofDEMISandMISO.Previousstudieshave
suggested that the incidence of peripheral
neuropathy, the dose-limiting factor for
MISO in man, is related to total tissue
exposure (AUC) (Dische et al., 1977;
Saunders et al., 1978). We have shown
that the plasma AUC for DEMIS is only
half that for the same i.v. dose of MISO.
In addition, brain and CSF/plasma ratios
were only halfthose for MISO, resulting in
an overall 4-fold reduction in total CNS
drug exposure. Significantly, recent studies
in the dog indicate a similar reduction in
total drug exposure to the peripheral
nerves (White et al., in preparation).
These factors may allow higher total
doses of DEMIS than of MISO to be ad-
ministered, with consequentimprovements
in the enhancement ratios. It is unlikely,
however, that DEMIS would be a suitable
hypoxic cell sensitizer for the treatment
of brain tumours within the blood/brain
barrier, because of its poor CNS penetra-
tion. The 50o higher peak plasma con-
centrations ofDEMIS than ofMISO repre-
sent still further advantage for the use
of this drug, though the data from this
study indicate that to achieve maximum
radiosensitization with DEMIS irradiation
would need to be shortly after i.v. dosage.
Furthermore, because of the poor and
variable oral absorption of DEMIS the
only suitable means of administration
would be i.v. injection. Although less con-
venient for clinical use than the oral route,
the i.v. administration of an appropriate
formulation of DEMIS should not pose a
major problem.
In view of the current dose limitation
for the clinical use ofMISO, it is clear that
an ideal hypoxic cell radiosensitizing drug
has yet to be described. The data from the
present study suggest considerable promise
for the development of less toxic alterna-
tivestoMISOinthefurtherinvestigationof
DEMIS and other 2-nitroimidazole radio-
sensitizing drugs which are less lipophilic
than MISO and which achieve substan-
tially reduced tissue exposure.
WVe wish to thank Professor N. M1. Bleeheln and
Dr L. N. Owen for their advice and continued sup-
port, Dr Nancy Smith and Mrs Jane Donaldson for
th-eir skilled technical assistance, AMiss Christine
Wright for typing, and the MTNIRC and CRC for
financial support.276 R. A. S. WHITE AND P. WORKMAN
REFERENCES
ADAMS, G. E., FLOCKHART, I. R., SMITHEN, C. E.,
STRATFORD, I. J., WARDMAN, P. & WATTS, M. E.
(1976) Electron-affinic sensitisation, VII: A
correlation between structures, one-electron re-
duction potential and efficiencies of nitroimid-
azoles as hypoxic cell radiosensitisers. Radiat. Res.,
67, 9.
ADAMS, G. E., CLARKE, E. D., FLOCKHART, I. R. & 8
others (1979a) Structure-activity relationships in
the development of hypoxic cell radiosensitisers,
I: Sensitisation efficiency. Int. J. Radiat. Biol., 35,
133.
ADAMS, G. E., CLARKE, E. D., FLOCKHART, I. R. &
8 others (1979b) Structure activity relationships
in the development ofhypoxic cell radiosensitisers,
II: Cytotoxicity and therapeutic ratio. Int. J.
Radiat. Biol., 35, 151.
ASH, D. V., SMITH, M. R. & BUGDEN, R. D. (1979)
Distribution of misonidazole in human tumours
and normal tissues. Br. J. Cancer, 29, 503.
BROWN, J. M., Yu, N. Y., CORY, M. J., BICKNELL,
R. B. & TAYLOR, D. L. (1978) In vivo evaluation
of the radiosensitising and cytotoxic properties of
newly synthesised electron-affinic drugs. Br. J.
Cancer, 37 (Suppl. III), 206.
BROWN, J. M., Yu, N. Y. & WORKMAN, P. (1979)
Pharmacokinetic considerations in testing hypoxic
cell radiosensitisers in mouse tumours. Br. J.
Cancer, 39, 310.
DISCHE, S., SAUNDERS, M. I., LEE, M. E., ADAMS,
G. E. & FLOCKHART, I. R. (1977) Clinical testing
of the radiosensitiser Ro 07-0582. Experience with
multiple doses. Br. J. Cancer, 35, 567.
FLOCKHART, I. R., MALCOLM, S. L., MARTEN, T. R.,
PARKINS, C. S., RUANE, R. J. & TROUP, D. (1978a)
Some aspects of the metabolism of misonidazole.
Br. J. Cancer, 37 (Suppl. III), 264.
FLOCKHART, I. R., SHELDON, P. W., STRATFORD,
I. J. & WATTS, M. E. (1978b) A metabolite of the
2-nitroimidazole misonidazole withradiosensitising
properties. Int. J. Radiat. Biol., 34, 91.
SAUNDERS, M. I., DISCHE, S., ANDERSON, P. &
FLOCKHART, I. R. (1978) The neurotoxicity of
misonidazole and its relationship to dose, half-life
and concentration in the serum. Br. J. Cancer, 37
(Suppl. III), 268.
URTASUN, R. C., BAND, P., CHAPMAN, J. D., RABIN,
H. R., WILSON, A. F. & FRYER, C. G. (1977)
Clinical phase 1 study of the hypoxic cell radio-
sensitiser Ro 07-0582, a 2-nitroimidazole deriva-
tive. Radiology, 122, 801.
WARDMAN, P., CLARKE, E. D., FLOCKHART, I. R. &
WALLACE, R. G. (1978) The rationale for the
development of improved hypoxic cell radio-
sensitisers. Br. J. Cancer, 37 (Suppl. III), 1.
WHITE, R. A. S., WORKMAN, P., FREEDMAN, L. S.,
OWEN, L. N. & BLEEHEN, N. M. (1979a) The
pharmacokinetics of misonidazole in the dog.
Eur. J. Cancer, 15, 1233.
WHITE, R. A. S., WORKMAN, P., OWEN, L. N. &
BLEEHEN, N. M. (1979b) The penetration of
misonidazole into spontaneous canine tumours.
Br. J. Cancer, 40, 284.
WILTSHIRE, C. R., WORKMAN, P., WATSON, J. V. &
BLEEHEN, N. M. (1978) Clinical studies with
misonidazole. Br. J. Cancer, 37 (Suppl. III), 286.
WORKMAN, P., LITTLE, C. J., MARTEN, T. R. & 4
others (1978) Estimation of the hypoxic cell
sensitiser misonidazole and its 0-demethylated
metabolite in biological material by reversed-
phase high-performance liquid chromatography.
J. Chromatogr., 145, 507.
WORKMAN, P. (1979) Effects of pretreatment with
phenobarbitone and phenytoin on the pharmaco-
kinetics and toxicity of misonidazole in mice.
Br. J. Cancer, 40, 335.